A O Olsen1, J Dillner, K Gjøen, P Magnus. 1. Department of Population Health Sciences, National Institute of Public Health, Oslo, Norway.
Abstract
OBJECTIVES: To assess if seropositivity to human papillomavirus type 16 capsids is a better marker of sexual history than the presence of HPV DNA. STUDY DESIGN: A population based age stratified random sample of 234 Norwegian women (mean age 32.8 years, range 20-44) was examined for HPV serum antibodies, cervical HPV DNA, cytology and age in relation to sexual behaviour. RESULTS: Neither age nor age at first sexual intercourse was associated with HPV 16 antibodies. Adjusted ORs for 4-5; 6-10 and > 10 versus 0-1 lifetime sexual partners, were 13.1 (95% CI 1.5-110.8), 8.2 (1.0-69.6) and 10.5 (1.2-94.0) for HPV 16 seropositivity, respectively; and 2.6 (0.2-27.8), 3.4 (0.4-31.7) and 4.1 (0.4-42.8) for HPV 16 DNA positivity, respectively. CONCLUSION: Seropositivity to HPV 16 capsids is positively associated with the number of sexual partners, suggesting that HPV 16 is predominantly sexually transmitted. The fact that serology had a stronger association with number of sexual partners than viral DNA suggests that seroreactivity is a better measure of lifetime history of HPV infection.
OBJECTIVES: To assess if seropositivity to human papillomavirus type 16 capsids is a better marker of sexual history than the presence of HPV DNA. STUDY DESIGN: A population based age stratified random sample of 234 Norwegian women (mean age 32.8 years, range 20-44) was examined for HPV serum antibodies, cervical HPV DNA, cytology and age in relation to sexual behaviour. RESULTS: Neither age nor age at first sexual intercourse was associated with HPV 16 antibodies. Adjusted ORs for 4-5; 6-10 and > 10 versus 0-1 lifetime sexual partners, were 13.1 (95% CI 1.5-110.8), 8.2 (1.0-69.6) and 10.5 (1.2-94.0) for HPV 16 seropositivity, respectively; and 2.6 (0.2-27.8), 3.4 (0.4-31.7) and 4.1 (0.4-42.8) for HPV 16 DNA positivity, respectively. CONCLUSION: Seropositivity to HPV 16 capsids is positively associated with the number of sexual partners, suggesting that HPV 16 is predominantly sexually transmitted. The fact that serology had a stronger association with number of sexual partners than viral DNA suggests that seroreactivity is a better measure of lifetime history of HPV infection.
Authors: A Hildesheim; M H Schiffman; P E Gravitt; A G Glass; C E Greer; T Zhang; D R Scott; B B Rush; P Lawler; M E Sherman Journal: J Infect Dis Date: 1994-02 Impact factor: 5.226
Authors: A Hildesheim; P Gravitt; M H Schiffman; R J Kurman; W Barnes; S Jones; J G Tchabo; L A Brinton; C Copeland; J Epp Journal: Sex Transm Dis Date: 1993 Sep-Oct Impact factor: 2.830
Authors: H M Bauer; A Hildesheim; M H Schiffman; A G Glass; B B Rush; D R Scott; D M Cadell; R J Kurman; M M Manos Journal: Sex Transm Dis Date: 1993 Sep-Oct Impact factor: 2.830
Authors: F X Bosch; N Muñoz; S de Sanjosé; C Navarro; P Moreo; N Ascunce; L C Gonzalez; L Tafur; M Gili; I Larrañaga Journal: Cancer Epidemiol Biomarkers Prev Date: 1993 Sep-Oct Impact factor: 4.254
Authors: L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat Journal: N Engl J Med Date: 1992-10-29 Impact factor: 91.245
Authors: M H Schiffman; H M Bauer; R N Hoover; A G Glass; D M Cadell; B B Rush; D R Scott; M E Sherman; R J Kurman; S Wacholder Journal: J Natl Cancer Inst Date: 1993-06-16 Impact factor: 13.506
Authors: Caihua Liang; Carmen J Marsit; Michael D McClean; Heather H Nelson; Brock C Christensen; Robert I Haddad; John R Clark; Richard O Wein; Gregory A Grillone; E Andres Houseman; Gordana Halec; Tim Waterboer; Michael Pawlita; Jeffrey F Krane; Karl T Kelsey Journal: Cancer Res Date: 2012-09-18 Impact factor: 12.701
Authors: Beibei Lu; Raphael P Viscidi; Ji-Hyun Lee; Yougui Wu; Luisa L Villa; Eduardo Lazcano-Ponce; Roberto J Carvalho da Silva; Maria Luiza Baggio; Manuel Quiterio; Jorge Salmerón; Danelle C Smith; Martha Abrahamsen; Mary Papenfuss; Heather G Stockwell; Anna R Giuliano Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-03-04 Impact factor: 4.254
Authors: Beibei Lu; Raphael P Viscidi; Yougui Wu; Alan G Nyitray; Luisa L Villa; Eduardo Lazcano-Ponce; Roberto J Carvalho da Silva; Maria Luiza Baggio; Manuel Quiterio; Jorge Salmerón; Danelle C Smith; Martha Abrahamsen; Mary Papenfuss; Anna R Giuliano Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-07-03 Impact factor: 4.254
Authors: Andrea Trevisan; João M G Candeias; Patrícia Thomann; Luisa L Villa; Eduardo L Franco; Helen Trottier Journal: J Med Microbiol Date: 2020-07 Impact factor: 2.472
Authors: Jia Ji; Hai-Kui Sun; Jennifer S Smith; He Wang; Mark T Esser; Shangying Hu; Robert G Pretorius; Wen Chen; Jerome L Belinson; You-Lin Qiao Journal: BMC Infect Dis Date: 2012-06-20 Impact factor: 3.090
Authors: Reinhard Höpfl; Anton Petter; Petra Thaler; Mario Sarcletti; Andreas Widschwendter; Robert Zangerle Journal: BMC Infect Dis Date: 2003-04-30 Impact factor: 3.090
Authors: L Kjellberg; G Hallmans; A M Ahren; R Johansson; F Bergman; G Wadell; T Angström; J Dillner Journal: Br J Cancer Date: 2000-04 Impact factor: 7.640